Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
NEJM Evidence|May 30, 2024
Prostate Cancer Foundation Screening Guidelines for Black Men in the United StatesIsla P Garraway, Sigrid V Carlsson, Yaw A Nyame, et al.
Cancer Research|May 25, 2019
Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic ProgressionRobert M Hughes, Brian W Simons, Hamda Khan, et al.
JAMA Network Open|January 18, 2022
Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care SystemKosj Yamoah, Kyung Min Lee, Shivanshu Awasthi, et al.
Cancer|July 19, 2025
Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health AdministrationAshley-Marie Y Green-Lott, Ananta Wadhwa, Anissa V Bailey, et al.
BMC Cancer|April 3, 2019
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseNeil R Parikh, Claudia Huiza, Jill S Patel, et al.
Nature Medicine|November 28, 2018
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axisMirja Rotinen, Sungyong You, Julie Yang, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 15, 2025
Association of HOXB13 G84E With Prostate Cancer Among 592,158 MenTaylor B Crawford, Tyler Nelson, Roshan Karunamuni, et al.
European Urology Oncology|June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed TherapyJesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate CancerChen Qian, Qian Yang, Mirja Rotinen, et al.
Pageof 7